We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-10.52%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
-$86.9M
Cap. Flow
-$24.2M
Cap. Flow %
-7.71%
Top 10 Hldgs %
50.55%
Holding
86
New
32
Increased
12
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$18.5M
2
SRRK icon
Scholar Rock
SRRK
+$15.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.5M
4
QURE icon
uniQure
QURE
+$8.99M
5
CGON icon
CG Oncology
CGON
+$8.15M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$18M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.2M
3
INCY icon
Incyte
INCY
+$13.4M
4
MRUS
Merus
MRUS
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
76
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-101,809
Closed -$4.28M
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$378M
– –
-270,983
Closed -$3.41M
SLRN
78
DELISTED
ACELYRIN
SLRN
– –
-1,704,825
Closed -$5.35M
SNDX icon
79
CALL
Syndax Pharmaceuticals
SNDX
$1.99B
– –
-234,100
Closed -$51K
SPY icon
80
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
– –
-85,000
Closed -$414K
SRRK icon
81
CALL
Scholar Rock
SRRK
$6.25B
– –
-100,000
Closed -$228K
TRML
82
DELISTED
Tourmaline Bio
TRML
– –
-126,400
Closed -$2.56M
VRNA
83
DELISTED
Verona Pharma
VRNA
– –
-28,136
Closed -$1.31M
CTNM
84
Contineum Therapeutics
CTNM
$522M
– –
-265,833
Closed -$3.89M
ATYR
85
aTyr Pharma
ATYR
$48.9M
– –
-200,475
Closed -$726K
TECX
86
Tectonic Therapeutic
TECX
$599M
– –
-9,434
Closed -$436K
1 2 3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Stempoint Capital held 86 positions worth $314M, down 22% from $401M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital withdrew a net $24.2M in Q1 2025, closing 25 positions and reducing 15 holdings. Its most notable exit was Crinetics Pharmaceuticals, an estimated $16.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Arcellx worth $18M.

  • Stempoint Capital's largest Q1 2025 buy was Arcellx: 273,774 shares worth $18M.
  • Stempoint Capital added most to Scholar Rock in Q1 2025, an estimated $15.4M increase.
  • Stempoint Capital's biggest Q1 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $18M.
  • Stempoint Capital fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $16.2M.
  • Stempoint Capital's ten largest holdings make up 51% of its $314M portfolio in Q1 2025.
  • Stempoint Capital opened 32 new positions and closed 25 in Q1 2025.
  • Stempoint Capital's portfolio value fell 22% quarter-over-quarter to $314M.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.